Blinatumomab

• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 Phase III 11 countries Charite Universitaetsmedizin Berlin KöR
• A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending
  2025-521671-31-00 Phase I/II 3 countries Amgen Inc.
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 Phase I/II 7 countries Novartis Pharma AG
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 Phase II/III 9 countries Ospedale Pediatrico Bambino Gesu
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-… Recruiting
  2025-520982-39-00 Phase III 13 countries Universita Degli Studi Di Milano Bicocca
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 Phase III 19 countries Princess Maxima Center For Pediatric Oncology
• ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting
  2024-512657-24-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting
  2024-511437-35-00 Phase II/III 2 countries Assistance Publique Hopitaux De Paris
• A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatmen… Recruiting
  2025-523061-22-00 Phase II 1 country Universitaet Leipzig
• EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib… Recruiting
  2023-505330-95-01 Phase II 3 countries Cardiff University
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 Phase II 1 country Goethe University Frankfurt
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 Phase II/III 14 countries Karolinska University Hospital
• An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr… Ended
  2024-517959-12-00 Phase I/II 1 country Goethe University Frankfurt
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III 17 countries Amgen Inc.
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended
  2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
• A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted
  2023-506136-32-00 Phase I/II 7 countries Amgen Inc.
• Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended
  2024-511050-44-00 Phase II 2 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Showing 1–19 of 19 trials